Vivo Capital

Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.

BiotechHealthtechMedical DevicesNorthbrook, US

Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)Patrick Morris(Secretary and Treasurer)Robert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)

BoardAaron Royston(Director)in

Board seatJack Nielsen· per SEC Form D · $50M raise · filed Aug 2019

Co-investorsAisling CapitalParagon Biosciences LLCValor Equity PartnersvenBio Partners

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.

BiotechDigital HealthFemTechHealthtechSalt Lake City, US

Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)Gregory C. Critchfield(Executive Officer, Director)Andrew A. Sauter(Executive Officer)

BoardMansoor Mirza(Director)Ryan M. Trimble(Director)

Board seatJoseph Siletto· per SEC Form D

Co-investorsaMoonExcelestar VenturesOUP (Osage University Partners)UpStart VenturesCatalyst Health VenturesDomain Associates

Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.

BiotechHealthtechMorristown, US

Scott Giacobello(Executive Officer)Bryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)David Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)

Co-investors3B Future Health FundAlly Bridge GroupDecheng CapitalAvoro VenturesOrbiMed

Achieve Life Sciences is a late-stage specialty pharmaceutical company developing cytisinicline, a treatment for nicotine dependence and smoking cessation.

BiotechHealthtechVancouver, B.C., US

Anthony Clarke(Executive Officer)Richard Stewart(Director)Cindy Jacobs(Executive Officer, Director)Jaime Xinos(Executive Officer)John Bencich(Executive Officer, Director)

BoardBridget Martell(Director)

Co-investorsvenBio PartnersFrazier Life Sciences

Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.

BiotechHealthtechMedical DevicesWayne, US

Neal Walker(Executive Officer, Director)Kamil Ali-Jackson(Executive Officer)Stuart D. Shanler(Executive Officer)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)

Co-investorsAisling CapitalAPERTURE Venture PartnersF-Prime CapitalForesite CapitalRA CapitalSofinnova Ventures+1 more

Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates.

BiotechDigital HealthMental HealthMountain View, US

Amit Etkin(Founder)inAdam Savitz(Executive Officer)Nicholas C. Smith(Executive Officer)Michael Hanley(Executive Officer)Aaron Weaver(Director)Po Yu (Jeff) Chen(Director)

Co-investorsAble PartnersAlpha Wave GlobalInVivium CapitalK2 HealthVenturesKorify CapitalWhat If Ventures+2 more

Bolt Biotherapeutics develops cancer immunotherapies that use the innate immune system to help the body recognize and eliminate tumor cells.

Co-investorsPfizer Venture InvestmentsRA CapitalSamsara BioCapitalSofinnova VenturesNan Fung Life SciencesNovo Holdings+1 more

Compass Pathways develops psychedelic-based treatments for mental health conditions, aiming to create a new clinical standard for patients underserved by current care.

BiotechDigital HealthMental Health

Co-investorsAble PartnersAisling CapitalCatalio Capital Management, LPNoeticOMX VenturesJam Fund

Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer.

BiotechHealthtechCambridge, US

Schuetz Thomas(Executive Officer, Director)Errik Anderson(Executive Officer, Director)Steve Tregay(Director)

Co-investorsBioBritF-Prime CapitalForesite CapitalOrbiMedvenBio Partners

Instil Bio is a biotechnology company that identifies and develops therapeutic opportunities.

BiotechDallas, US

Bronson Crouch(Chief Executive Officer & Chairman of the Board)inSandeep "Steve" Laumas(Chief Financial Officer & Chief Business Officer)Nimish Shah(Director)Gwen Binder(Director)Neil Gibson(Director)George Matcham(Director)

Co-investorsCurative Ventures

Mereo BioPharma is a biopharmaceutical company that develops novel therapies for rare diseases with limited or no treatment options, focusing on lead programs in osteogenesis imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD).

BiotechLondon

John Richard(Head of Corporate Development and Co-Founder)Dr. Denise Scots-Knight(Chief Executive Officer and Co-Founder)Charles Sermon(General Counsel and Co-Founder)Richard Jones(Chief Financial Officer)Jill Henrich(Senior Vice President)

BoardDr. Deepa Pakianathan(Non-Executive Director)

Co-investorsPontifax Venture Capital

Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders.

BiotechHealthtechWaltham, US

Joseph Reilly(Executive Officer)Geoff Race(Executive Officer)Fred Ahlholm(Executive Officer)Remy Luthringer(Executive Officer, Director)Mark Levine(Executive Officer)

BoardMichele Ollier(Director)in

Co-investorsMedicxi

Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies.

BiotechDeep TechHealthtechVenice, US

Lawrence Steinman(Director)Tiago Reis Marques(Director)Israel Maxx Abramowitz(Executive Officer, Director)Craig Auringer(Executive Officer, Director)

Co-investorsJanus Henderson Investors

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)Derek Jantz(Co-founder)TODD MELBY(Executive Officer)

Co-investorsage1Aliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+4 more

BiotechLondon

James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)

Co-investorsForesite CapitalMC Healthcare VenturesNextech Invest

Tarsus Rx is a pharmaceutical company developing treatments for diseases with high unmet need, with a lead product XDEMVY (lotilaner ophthalmic solution) approved by the FDA for Demodex blepharitis.

BiotechHealthtechMedical Devices

Bobak Azamian, MD, PhD(Founder)in

Co-investorsAPERTURE Venture PartnersFlying L PartnersFrazier Life SciencesVisionary VenturesBain Capital Life SciencesRTW Investments L.P.

Tenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).

BiotechDigital HealthHealthtechChapel Hill, US

Stuart Rich(Chief Medical Officer)Lawrence R. Hoffman(Interim Chief Financial Officer)Christopher T. Giordano(President and Chief Executive Officer)Michael B. Jebsen(Executive Officer)Chris Giordano(President and Chief Executive Officer)Doug Randall(Chief Business Officer)

Co-investorsQiming Venture PartnersYuanBio Venture Capital

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)

BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersQuan CapitalSR One Capital Management+1 more

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.

BiotechHealthtechMedical DevicesDenmark, DK

Jan Møller Mikkelsen(Founder, President and Chief Executive Officer)James Healy(Director)Grethe Rasmussen(Executive Officer)Harald Rau(Executive Officer)Rafa?le Tordjman(Director)Martin Olin(Director)

Co-investorsAisling CapitalAvoro Capital AdvisorsForesite CapitalRA CapitalSofinnova Ventures

Neocis develops Yomi, a robotic surgical platform that assists clinicians during dental implant surgery with planning, surgical, and restorative software features.

HealthtechMedical DevicesRoboticsMiami, US

Alon Mozes(CEO & Co-Founder)inJuan Salcedo(Engineering Fellow & Co-Founder)inJUAN SALCEDO(Executive Officer)inALON MOZES(Executive Officer, Director)Dennis Moses(Chief Technical Officer)inAndres Carrillo(VP of Product)in

Co-investorsIntuitive VenturesNorwest Venture PartnersMITHRILB Capital GroupMirae Asset Venture InvestmentMithril Capital Management+1 more

Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer.

BiotechDeep TechHealthtechShanghai, CN

Helen Yang(Founder)in

Co-investorsQiming Venture PartnersQuan Capital

ABK Biomedical is a clinical-stage medical device company that develops x-ray visible glass microspheres for Y-90 radioembolization and embolic treatment of cancers such as liver cancer.

BiotechHealthtechMedical DevicesHalifax, CA

Bob Abraham(Executive Officer, Director)Robert Abraham(Co-founder (Interventional Radiologist, MD))Daniel Boyd(Co-founder (Material Scientist))Sharon Kehoe(Co-founder (Material Scientist))Anthony Headley(Executive Officer)Gary Donofrio(Executive Officer)

Board seatJoseph Siletto· per SEC Form D · $2.6M raise · filed Nov 2025

Co-investorsEight Roads VenturesF-Prime Capital

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.

BiotechHealthtechSouth San Francisco, US

Leonid Beigelman(President)inLawrence M. Blatt(Chairman, President & CEO (Co-founder))inHardean Achneck(Executive Officer)Sushmita Chanda(Executive Vice President - Preclinical Development)Brian Dowd(Executive Vice President - Controller)Lucinda Quan(Executive Vice President - General Counsel)

Board seatJack Nielsen· per SEC Form D · $92.2M raise · filed Nov 2023

Co-investorsRoche Venture FundMPM BioVentures 2014

BiotechSan Diego, US

Francois Ferre(Director)Magda Marquet(Director)Jorge Garces(Executive Officer)Greg Hamilton(Executive Officer, Director)Carin Sandvik(Executive Officer)Jeffrey G. Black(Executive Officer)

Board seatYuh-geng Tsay· per SEC Form D · $3M raise · filed Mar 2018

Co-investorsBioBrit

Amyris develops a biomanufacturing platform that uses fermentation and microbial engineering to produce natural ingredients and rare compounds at scale for partners across industries such as specialty chemicals, food ingredients, and consumer products.

Advanced ManufacturingBiotechCleantechNew MaterialsEmeryville, US

NICHOLAS KHADDER(Senior Vice President, General Counsel & Secretary)RAFFI ASADORIAN(Chief Financial Officer)Joel Cherry(President, Research & Development)Tamara Tompkins(Executive Vice President, General Counsel)John Melo(President & Chief Executive Officer)Paulo Diniz(Chief Financial Officer)

Board seatFrank Kung· per SEC Form D · $38.1M raise · filed Apr 2018

Co-investorsKleiner PerkinsR7 Partners

Pleasanton, US

Chih-Ping Liu(Executive Officer, Director, Promoter)

BoardEdgar G Engleman(Director)

Board seatEdgar G. Engleman· per SEC Form D · $93.5M raise · filed Jan 2021

Co-investorsSofinnova Ventures

HealthtechRedwood City, US

Gina Phelps(Executive Officer)David D. O'Toole(Executive Officer)Anish Bhatnagar(Executive Officer, Director)Anthony Wondka(Executive Officer)

BoardSteinar Engelsen(Director)

Board seatEdgar G. Engleman· per SEC Form D · $3.7M raise · filed Mar 2015

BiotechSanta Clara, US

Jeffrey Glenn(Director)David Cory(Executive Officer, Director)

BoardNina Kjellson(Director)inEd Engleman(Director)

Board seatEdgar G. Engleman· per SEC Form D · $3M raise · filed Apr 2016

Co-investorsPfizer Venture InvestmentsCanaan Partners

Mediaspace is a digital agency that designs and builds custom Squarespace websites and provides SEO, digital marketing strategy, and digital advertising services.

AdTechAdvanced ManufacturingAI & Machine LearningData & InfrastructureDigital HealthEnterprise SoftwareHardwareHealthtechMarketing TechMedical DevicesSemiconductorsAtlanta, US

John G. Edwards(Executive Officer, Director)John Jacobi(Executive Officer)Sri Peruvemba(Executive Officer)Francois Jeanneau(Executive Officer, Director)Linda Ara(Executive Officer)Michael Vestel(Executive Officer)

Board seatNathan DauJack Nielsen· per SEC Form D · $22M raise · filed Dec 2021

Co-investors3E Bioventures CapitalKeiretsu ForumLife Sciences Greenhouse InvestmentsToba Capital

Houston, US

Board seatJoseph Siletto· per SEC Form D · $45M raise · filed Jul 2020

Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.

BiotechDeep TechHardwareHealthtechCambridge, US

Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)

BoardVictor Tong(Director)Thomas Grogan(Director)

Board seatYuh-geng Tsay· per SEC Form D · $23M raise · filed Sep 2016

Co-investorsLAVLilly Asia VenturesLilly Ventures

Plano, US

Board seatJack Nielsen· per SEC Form D · $50M raise · filed Jun 2020

Scientia Vascular develops guidewires, including the Aristotle and Zoom Wire product lines, for general vascular use within the neuro and peripheral vasculatures to introduce and position catheters and other interventional devices.

HealthtechMedical DevicesWest Valley City, US

John Lippert(Executive Officer, Director)Stacy Lippert(Executive Officer, Director)

BoardJeffrey Gladden(Dr. Gladden is a manager of the issuer.)David Bearss(Mr. Bearss is a manager of the issuer.)Rick Randall(Mr. Randall is a manager of the issuer.)Jerry Henley(Mr. Henley is a manager of the issuer.)

Board seatNathan DauJoseph Siletto· per SEC Form D

Co-investorsCowles Ventures

HealthtechIrvine, US

Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)

Board seatJoseph Siletto· per SEC Form D

Co-investorsBlackRockEndeavour VisionMVM Life Science PartnersRTW Investments L.P.Soleus CapitalvenBio Global Strategic

35Pharma is a biopharmaceutical company that designs and develops ligand traps targeting the Activin x GDF signaling pathway to treat pulmonary hypertension, heart failure, and obesity.

BiotechHealthtech

Co-investorsFrazier Life SciencesvenBio PartnersJanus Henderson Investors

ADARx is a clinical-stage biopharmaceutical company developing RNA-based medicines using its RNA science expertise and proprietary targeted delivery platforms to silence disease-causing genes.

BiotechMedical Devices

Co-investorsOrbiMedTCG Crossover

ADAXION develops deimmunized biologic therapies using its ADAx platform, which incorporates proprietary CD22 ligands to eliminate therapeutic-specific B cells and reduce anti-drug antibody responses.

BiotechDeep Tech

Co-investorsJDRF T1D Fund

Aerobiotix makes Illuvia Sense, a surgical air purification device that combines HEPA filtration, ultraviolet germicidal light, and environmental sensors to reduce airborne contamination and surgical site infection risk in operating rooms.

HardwareHealthtechMedical Devices

Co-investorsHorizon Technology Finance

Agno Pharmaceuticals is a contract development and manufacturing organization providing services from active pharmaceutical ingredient (API) development and drug product formulation to cGMP manufacturing for clinical trials and commercial production of APIs, chemical intermediates, and drug products.

Advanced ManufacturingBiotechHealthtech

Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery.

AI & Machine LearningBiotechHealthtechNew York, US

Martin Vogelbaum(Co-founder & Board Member)Ross Levine(Director)Ramy Farid(Director)

BoardScott Platshon(Director)

Co-investorsInning One VenturesEcoR1 Capital

Akira Bio develops therapies for people living with sickle cell disease and other hemoglobinopathies.

BiotechHealthtech

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

Jonathan Wall(Executive Officer)Spencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)Benson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)

Co-investorsAlpha Wave GlobalBioBritvenBio PartnersvenBio Global Strategic

Co-investorsAvoro Capital AdvisorsTrinity Innovation Bioventure Singapore

BH Therapeutics is a drug development company that uses structure-based rational drug design to identify structural limitations in existing therapies and design novel chemical scaffolds to address them.

Biotech

Co-investorsOrbiMed

Biodlink is a contract development and manufacturing organization (CDMO) focused on biologics, including monoclonal antibody drug substances and antibody-drug conjugates (ADCs).

Advanced ManufacturingBiotechHealthtech

Bonray Bio (邦睿生技) develops precision medical devices and optical technology for male fertility testing under the LensHooke brand, including sperm routine analysis, sperm DNA fragmentation testing, and sperm washing devices.

FemTechHealthtechMedical Devices

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.

BiotechHealthtechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in

BoardSamuel Bjork(Director)inMonique Schiersing(Director)inJohn McKearn(Director)in

Co-investorsRiverVest Venture PartnersRoche Venture Fund3x5 PartnersCodon CapitalDigitalis Ventures

Caidya is a contract research organization (CRO) that combines scientific, medical, and operational expertise to manage complex clinical development and cross-border trials.

BiotechDigital HealthHealthtech

Co-investorsHatteras Venture Partners

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)

Co-investorsAtlas VentureBain Capital Life SciencesJanus Henderson InvestorsLAVOmega FundsvenBio Global Strategic+1 more

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)Ken Bartizal(Executive Officer)Paul Daruwala(Executive Officer)

Co-investors5AM VenturesAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalCanaan Partners+1 more

Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.

BiotechHealthtechCambridge, US

Co-investorsCatalio Capital Management, LPCure VenturesCatalio Capital ManagementNovo HoldingsThird Rock Ventures

Landos Technology (朗来科技) is a clinical-stage drug discovery and development company with a pipeline of novel small-molecule therapies for indications including hypertension, chronic heart failure, IgA nephropathy, FSGS, chronic cough, idiopathic pulmonary fibrosis, and autoimmune diseases such as rheumatoid arthritis and psoriasis.

BiotechHealthtechWuhan, CN

Co-investorsOrbiMedLilly Asia Ventures

Dutscher is a distributor of laboratory products and equipment—including pipettes, PCR plates, filter tips and consumables—serving scientific and research laboratories.

B2B MarketplacesBiotechE-commerce

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)

Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundRoche Venture FundSamsara BioCapital+3 more

Esco Aster is a Singapore-based contract research, development, and manufacturing organization (CRDMO/CDMO/CMO) offering end-to-end services from consultancy and process development through GLP tox, clinical trials, and commercial-scale biomanufacturing, built around its patented adherent-cell Tide Motion bioreactor platform.

BiotechFoodTechMedical DevicesSingapore, SG

Esco Lifesciences manufactures laboratory and biopharma equipment, including clean air, containment, and laboratory technologies, as well as IVF/ART medical devices for clinical and industrial laboratories, pharmaceutical companies, and fertility care providers.

BiotechHardwareMedical Devices

Co-investorsGICNovo Holdings